ANGLE’s ultimate objective is the widespread adoption of the Parsortix® system into treatment centers which specialize in the diagnosis and treatment of cancer patients.
According to the latest statistics, there were an estimated 18.1 million new cancer cases worldwide in 2020, a marked rise on the 14.1 million cases in 2012. In 2020, there were an estimated 44.1 million people living with cancer.1
The incidence of cancer continues to grow as a result of demographic, lifestyle and environmental factors and it is estimated that 40-50% of people will get cancer in their lifetime.2,3
There are a wide range of potential applications for harvested CTCs including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness, and remission monitoring.